Novavax | NVAX - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
Adma Biologics USD 57.13M 4.47M 2026-03
Agenus USD 39.21M 49.82M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Cassava Sciences USD -10.81M 33.41M 2025-09
Geron USD -3.64M 27.5M 2026-03
GlaxoSmithKline GBP 2.68B 532M 2026-06
MannKind USD -16.37M 4.56M 2026-03
Merck USD -3.53B 6.95B 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -1.33B 535M 2026-03
Novartis USD 3.84B 1.33B 2026-03
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD -653M 5.84B 2026-06
Sanofi EUR 837M 1.17B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
TG Therapeutics USD 10.23M 10.13M 2026-06